Nitromint (Glyceryl Trinitrate Solution)

Glyceryl trinitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels in smooth muscle cells, leading to relaxation of veins and arteries, lowering cardiac preload and afterload, and decreasing myocardial oxygen demand.

The dose of Nitromint is individualized by the prescribing clinician based on the severity of angina, patient response, and tolerability. The prescriber determines the number of sublingual sprays or drops needed for each episode and any prophylactic regimen.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Nitromint, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitromint belongs to the nitrate class, which provides rapid onset of action for acute angina relief. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle to lower cardiac workload, but they may cause headaches and require careful avoidance of other vasodilators.

Nitromint should be stored at room temperature, below 25 °C, in its original container. Protect the solution from moisture and direct light to maintain stability and potency throughout its shelf life.

Nitromint is a sublingual solution. The patient places the prescribed number of drops or sprays under the tongue and allows it to dissolve without swallowing. This route provides rapid absorption into the bloodstream for quick symptom relief.

The most serious risks include severe hypotension, which can lead to fainting or shock, and rare cases of methemoglobinemia or severe allergic reactions. Patients should be monitored for sudden drops in blood pressure and instructed to seek immediate medical attention if they experience these symptoms.

Nitromint is contraindicated in patients with known hypersensitivity to nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24–48 hours, and individuals with severe anemia or increased intracranial pressure. Clinicians should evaluate each patient’s medical history before prescribing.